Rezultati pretraživanja
  1. Apellis Pharmaceuticals, Top stock up 234% from low. Close: 43.33 VolvsAvg: 0.76 Liq: $27M

  2. prije 6 sati

    FIND OUT WHY THIS DISRUPTIVE TECH IS ALREADY INTEGRATED AND BEING FURTHER INTEGRATED WITH and many other big tech companies

  3. prije 8 sati

    M&A - balked on Purchase then tried to invalidate their Soliris patent for biosimilar - while on hold - AMGN could go around ALXN by buying - perhaps this is why APLS is making all time highs.

  4. prije 9 sati

    There is no Rx in trials -Gene Therapy, Monoclonal Abs, or small molecules -as advanced (2 1200 pt P3s due in 1yr) or as promising (47% effect on GA) in Geographic Atrophy as Pegcetacoplan.

  5. prije 10 sati

    quality bio with bullish weekly candle.

  6. 4. velj

    Able to run 4 miles, and not have to look at my charts all, because I got 3 winning positions. , ,

  7. 4. velj

    Who will miss a more assured near-term approval than or ?

  8. 4. velj

    Analyst, J Kim, in calling for 2024 EPS of $15.39, is implying will be earning in 2 indications - PNH And Geographic Atrophy- as only earns $10+/share from Soliris/Ultomiris in PNH + 3 other indications- Conservative w/10M Dry AMD pts in US & no current treatment

  9. 3. velj
  10. 3. velj

    , two Biotechs working higher out of consolidations after big moves on data over the past few months

  11. 2. velj
  12. 1. velj

    issued their FY2024 earnings per share estimates for in a research report issued to clients and investors on 1/7/20 OPY analyst J. Kim forecasts APLS will post earnings per share of $15.39 for the year. Oppenheimer has a “Buy” rating and a $62.00 target on the stock”

    Prikaži ovu nit
  13. 31. sij

    -Best Data in PNH & in Geographic Atrophy -both on C3 inhibition- with a peptide that crosses the blood brain barrier - positive P3 data in the former- P3 readout in 2021 in the latter- multiple autoimmune/Renal targets to follow, CNS Targets to come- will eclipse

  14. 31. sij

    : ARE YOU READY TO MISS THE NEXT , , , OR ? 💫THIS IS A INDUSTRY DISRUPTOR WORTH LOOKING INTO AND AT 5 YEAR LOWS

  15. 31. sij

    shakes out non-believers before data release, similar to did in Q4 19

  16. 31. sij

    “Precise mechanisms leading to ALS to be determined-now increasing evidence implicating components of the innate immune complement system in the onset & progression of its motor phenotypes.” Trying Soliris-monoclonal Ab blocked by BBB has APL-2 a peptide-it gets in.

  17. 29. sij

    headed to 50 imo

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.